Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Gerald Marit"'
Autor:
Charles Mesguich, Gerald Marit, Valerie Latrabe, Laurence Bordenave, Elif Hindié, Paul Perez, Julien Asselineau, Cyrille Hulin
Publikováno v:
JMIR Research Protocols, Vol 9, Iss 9, p e17850 (2020)
JMIR Research Protocols
JMIR Research Protocols
Background The International Myeloma Working Group recommends the use of 18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for treatment response evaluation, as it is superior to magnetic resonance imaging (MRI). H
Autor:
Michel Attal, Frédérique Orsini-Piocelle, Herve Avet Loiseau, Lotfi Benboubker, Carla Araujo, Mourad Tiab, Sabine Brechignac, Eric Voog, Laurent Garderet, Karim Belhadj, Margaret Macro, Jean-Richard Eveillard, Brigitte Pegourie, Gerald Marit, Carine Chaleteix, Claire Mathiot, Arnaud Jaccard, Pascal Lenain, Benoit Berge, Bruno Royer, Anne-Marie Stoppa, Aurore Perrot, Mohamad Mohty, Xavier Leleu, Frédérique Kuhnowski, Murielle Roussel, Cyrille Hulin, Sylvie Glaisner, Ingrid Lafon, Martine Escoffre-Barbe, Olivier Allangba, Lionel Karlin, Marc Wetterwald, Philippe Moreau, Thierry Facon, Jean Claude Eisenmann, Eric Jourdan
Publikováno v:
Blood. 138:2753-2753
Background: The role of maintenance lenalidomide in myeloma, following autologous stem cell transplantation (ASCT) or not, is well established. However, 29% of patients discontinue the treatment with a median duration of less than 2 years with an inc
Autor:
Paul G. Richardson, Hervé Avet-Loiseau, Benoit Dupas, Martine Escoffre-Barbe, Aurore Perrot, Eric Frampas, Caroline Bodet-Milin, Lotfi Benboubker, Michel Attal, Thierry Facon, Gerald Marit, Jean-Richard Eveillard, Florence Caillon, Cyrille Hulin, Véronique Dorvaux, Lionel Karlin, Carine Chaleteix, Denis Caillot, Anne-Marie Stoppa, Brigitte Pegourie, Philippe Moreau, Kamel Laribi, Laurent Garderet, Jean-Michel Nguyen, Nikhil C. Munshi, Kenneth C. Anderson, Aurélie Gaultier, Margaret Macro, Françoise Kraeber-Bodéré
Publikováno v:
Journal of Clinical Oncology. 35:2911-2918
Purpose Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We conducted a prospective trial in patients with MM aimed at comparing MRI and PET-CT
Autor:
Eric Jourdan, Carla Araujo, Eric Voog, Jean-Richard Eveillard, Murielle Roussel, Carine Chaleteix, Philippe Moreau, Claire Mathiot, Jean-Claude Eisenmann, Mohamad Mohty, Michel Attal, Karim Belhadj, Bruno Royer, Arnaud Jaccard, Gerald Marit, Aurore Perrot, Martine Escoffre-Barbe, Frédérique Kuhnowski, Lofti Benboubker, Ingrid Lafon, Marc Wetterwald, Pascal Lenain, Laurent Garderet, Anne-Marie Stoppa, Benoit Berge, Thierry Facon, Cyrille Hulin, Xavier Leleu, Brigitte Pegourie, Olivier Allangba, Mourad Tiab, Sabine Brechignac, Margaret Macro, Frédérique Orsini-Piocelle, Herve Avet Loiseau, Sylvie Glaisner, Lionel Karlin
Publikováno v:
Blood. 132(24)
It is important to have an effective therapy for patients with multiple myeloma (MM) at first relapse, particularly if an autologous stem cell transplant (ASCT) is considered at this stage. This multicenter, phase 2 trial evaluated the efficacy and s
Autor:
Philip L. McCarthy, Sarah A. Holstein, Maria Teresa Petrucci, Paul G. Richardson, Cyrille Hulin, Patrizia Tosi, Sara Bringhen, Pellegrino Musto, Kenneth C. Anderson, Denis Caillot, Francesca Gay, Philippe Moreau, Gerald Marit, Sin-Ho Jung, Zhinuan Yu, Benjamin Winograd, Robert D. Knight, Antonio Palumbo, Michel Attal
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (29), pp.3279-3289. ⟨10.1200/JCO.2017.72.6679⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (29), pp.3279-3289. ⟨10.1200/JCO.2017.72.6679⟩
Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c90cd491ac014a1bbef57b2f6073ac
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01697539
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01697539
Autor:
Thierry Facon, Supratik Basu, Olivier Decaux, Shen Zx, Troy H. Guthrie, Gerald Marit, Alessandro Corso, Nizar J. Bahlis, T de Revel, Annette Ervin-Haynes, Miquel Granell, Pierre Desjardins, Shang-Yi Huang, Jennifer Marek, Stoppa Am, Hareth Nahi, Guang Chen, Hilde Demuynck, Lars-Olof Mügge
Publikováno v:
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia
The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66267dcdbfc355f9d6234c1422b1ebcf
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6043
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6043
Autor:
Didier Adiko, Josy Reiffers, Caroline Bureau, Franck-Emmanuel Nicolini, Gerald Marit, Stephane Morisset, Marie-Pierre Fort, Gabriel Etienne, Isabelle Tigaud, Sandrine Hayette, Anna Schmitt, Madeleine Etienne, Eric Lippert, Stéphanie Dulucq, Francois-Xavier Mahon
Publikováno v:
Haematologica. 99:458-464
Sustained imatinib treatment in chronic myeloid leukemia patients can result in complete molecular response allowing discontinuation without relapse. We set out to evaluate the frequency of complete molecular response in imatinib de novo chronic phas
Autor:
Mathieu Puyade, Karim Belhadj, Brigitte Kolb, Carla Araujo, Arnaud Jaccard, Michel Attal, Odile Luycx, Thomas Dejoie, Bruno Royer, Laurent Garderet, Sylvie Glaisner, Pascal Lenain, Denis Caillot, Anne-Marie Stoppa, Karim Laribi, Hélène Caillon, Jean-Claude Eisenmann, Hervé Avet-Loiseau, Lucie Planche, Pascal Godmer, Jean-Paul Fermand, Philippe Rodon, Murielle Roussel, Marc Wetterwald, Jean-Valère Malfuson, Gerald Marit, Martine Escoffre, Laetitia Biron, Philippe Moreau, Mamoun Dib, Jean Fontan, Thierry Facon, Driss Chaoui, Brigitte Pegourie, Carine Chaleteix, Borhane Slama, Cyrille Hulin, Mourad Tiab, Sabine Brechignac, Margaret Macro, Olivier Allangba, Véronique Dorvaux
Publikováno v:
Blood. 127(21)
The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-thalidomide-dexamethasone (VTD) with bortezomib-cyclophosphamide-dexamethasone (VCD) as induction before high-dose therapy and autologous stem cell transplantat
Autor:
Brigitte Pegourie, Martine Escoffre-Barbe, Denis Caillot, Philippe Rodon, Olivier Decaux, Laurent Garderet, Claire Mathiot, Brigitte Kolb, Stoppa Am, Anne Banos, Bertrand Arnulf, M. Attal, Thierry Facon, Sabine Brechiniac, Bruno Royer, Guillemette Fouquet, Marc Wetterwald, Hervé Avet-Loiseau, Jean Paul Fermand, Gerald Marit, Murielle Roussel, Lionel Karlin, M. Macro, Lotfi B Benbouker, Valentine Richez, Marie-Odile Petillon, Xavier Leleu, Philippe Moreau, C. Hulin
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
Annals of Oncology, Oxford University Press (OUP), 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
Annals of Oncology, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
Annals of Oncology, Elsevier, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
Annals of Oncology, Oxford University Press (OUP), 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
Annals of Oncology, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
International audience; Background - The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had a prolonged progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103306da23b03737efae536ad967d487
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01263111/document
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01263111/document
Autor:
Ibrahim Yakoub-Agha, Chantal Doyen, Thierry Facon, Robert Zerbib, Christian Berthou, Jean-Yves Mary, Philippe Casassus, Jean-Luc Harousseau, Philippe Rodon, Laurent Voillat, Cyrille Hulin, Ghandi Damaj, Mohamad Mohty, Borhane Slama, Frédéric Maloisel, Gerald Marit, Mamoun Dib, Lotfi Benboubker, Brigitte Pegourie, Philippe Moreau, Anne-Marie Stoppa
Publikováno v:
European Journal of Haematology. 88:249-259
This multicentre prospective randomised trial compared the efficacy and safety of two doses of thalidomide in patients with relapsed or refractory myeloma. The study was designed to test the non-inferior efficacy and to confirm the better tolerabilit